Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03951870
Other study ID # 0664-17-TLV
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 20, 2019
Est. completion date August 28, 2022

Study information

Verified date July 2022
Source Tel-Aviv Sourasky Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to characterize the link between neurobehavioral measures of the mesolimbic reward system and immune functioning in healthy individuals, via fMRI neurofeedback modulation of mesolimbic reward system, and the consecutive assesment of immune response to Hepatitis B vaccination.


Description:

For many years, the link between mental processes and physical health has remained obscure. Yet, over time, studies have begun to shed light on the intimate relationship between one's physical condition and mental state. One body of research aimed at elucidating the mind-body relationship is the study of the placebo effect. Placebo effects result mainly from conscious expectations to become healthy in therapeutic settings, and from unconscious conditioned responses to therapeutical settings that predict beneficial outcomes. Both processes are asociated with the neuronal reward system, which mediates reward processing, reward valuation and value based-learning. However, it remains unclear how do these processes mediated by the reward system promote therapeutic effects? A recent study established a causal relationship between mesolimbic activation (VTA) and a measurable immunological response in mice. Stimulation of the VTA increased anti-bacterial immune functioning, an effect that was mediated by sympathetic nervous system, which is regulated by the brain and innervates all immune organs. In light of these findings, the current study aims to assess the relationship between reward-related brain activation and immune functions in humans. fMRI Neurofeedback, a task that allows individuals to self modulate specified neural patterns in real-time, will be used to induce mesolimbic activation, following which healthy individuals will vaccinate against Hepatitis B. Immunological effects will be assessed by comparing immunological measures with respect to Hepatitis B prior and following mesolimbic activation and Hepatitis B vaccination. The long-term goal of this study is to demonstrate a causal link between reward activation and an objective measurable physiological response of great significance, and to develop the means for individuals to exploit such mechanism for boosting immune functioning. i.e. to harness endogenous reward-related brain activation to strengthen the immune system, for clinical pathologies such as autoimmune diseases, maleble pathogens, cancer, etc.


Recruitment information / eligibility

Status Completed
Enrollment 85
Est. completion date August 28, 2022
Est. primary completion date August 28, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Healthy participants - Normal or corrected to normal vision - Compatibility with general MRI requirements Exclusion Criteria: - History of neurological or psychiatric diseases that lead to hospitalization - Have received Hepatitis B vaccination in the last 10 years - Memory/cognitive neurological impairments - Chronic heart disease, diabities, high blood pressure, or autoimmune disease.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Neuromodulation via fMRI Neurofeedback task
Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
Biological:
Hepatitis B vaccination
Subjects will be vaccinated against Hepatitis B

Locations

Country Name City State
Israel Functional Brain Center, Sourasky Medical Center Tel Aviv

Sponsors (2)

Lead Sponsor Collaborator
Tel-Aviv Sourasky Medical Center Technion, Israel Institute of Technology

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunological: change in anti HBs immunoglobins in plasma To measure antibody titers in plasma, blood samples will be taken at four time points: before neurofeedback training (-14d); before Hepatitis B vaccination (day 0), 14 days and 28 days after vaccination. Anti-HBs change will be defined as average levels post-vaccination (14 and 28 days) minus average levels pre-vaccination (-14 and 0 days).
*19.09.22: due to extensive variability in baseline levels, anti-HB change will be defined as fold change between pre-and post-vaccination TPs, instead of absolute differences (blinding unharmed).
The investigators predict that:
i.Simple group effect: experimental arm subjects (mesolimbic fMRI NF) will exhibit higher levels of anti-HBs change than both the active comparator group (control fMRI-NF) and the no-treatment group.
ii.Mesolimbic activation-Immunologic response correlation: mesolimbic activity during the neurofeedback task (across all NF participants) during the last session will predict anti-HBs levels following vaccination.
6 weeks
Primary Immunological: change in cytokines blood concentrations following vaccination To assess cytokine levels (e.g. IL-4, IL-6, TNFalpha, IFNgamma), the investigators will isolate peripheral blood mononuclear cells from the blood, and using flow cytometry analysis, characterize cytokine expression profile (initial intentions of using ELISA will be replaced due to quality tests (blinding unharmed) that showed poor signal, 28/12/21). As mere NF practice may affect cytokines levels, cytokines will be assessed in three time points - before NF training (-14d), before vaccination (day 0) and 3 days following vaccination. groupXtime (3X3) main effect and interactions will be inspected.
The investigators predict that:
i.Experimental arm group will exhibit higher levels of cytokines concentration that the active control group and natural history group.
ii.Mesolimbic activation-Immunologic response correlation: mesolimbic activity during the neurofeedback task (across all NF participants) during the last session will predict changes in cytokines blood concentrations.
17 days
Primary Reward Mesolimbic network (or control networks) BOLD activity during fMRI-NF task ROIs of Mesolimbic reward network (or control networks) will be defined as mentioned in arms description *see below. CSF voxels will be excluded from all ROIs. Outcome will be measured for each experimental group/control sub-group, as the contrast between regulation and watch conditions, for each NF run, each session (3*4=12 runs).
To assess differences in meoslimbic reward network activation between experimental and active control groups, a 12 by 2 (runXgroup) model will be constructed.
*23/8/22 to exploit superior offline processing, ROIs will be deifned via group instead of online individual subs analysis.
The investigators predict that:
i. Simple group effects during last (fourth) NF session: experimental arm subjects (mesolimbic fMRI NF) will exhibit higher meoslimbic reward network activity than the active comparator group.
ii. Simple experimental arm group learning effects: a significant effect of run (time) for the experimental arm mesolimbic reward network acitivity.
1-3 weeks
Secondary Mental Strategies Questionnaire for NeuroFeedback (MSQ-NF) For each NF cycle in their training, subjects will fill out the MSQ-NF, a quesitonnaire that characterize mental strategies according to a hierarchical mental categorization.
Exploratory analysis: The investigators suspect that mental features that relate to motivation and reward processing will be associated with reward mesolimbic activity during NF training, and that such mental features will be associated post-practice immunological effects.
6 weeks
Secondary Neurobehavioral measures of reward anticipation and responsivity during Monetary Incentive Delay (MID) task. Neurobehavioral measures of reward responsitivity and reward anticipation will be assessed via application of MID task during fMRI scanning at the beginning of the first fMRI session (for all three study groups).
The investigators intend to explore whether neural and behavioral indices of reward anticipation and consumption could account for differences in immunological outcome measures, as defined above (see primary outcome measures).
Specifically, the investigators predict that:
i. BOLD responses to reward anticipation will be positively correlated with immunological outcome measures - Cytokines levels change and HBV antibodeis change (as defined above).
6 weeks
Secondary Behavioral measures of incentive motivation extracted from Effort Expenditure for Rewards Task (EEfRT). Behavioral measures of incentive saliance and incentive motivation will be assessed via application of EEfRT at the beginning of the first experimental session (for all three study groups).
The investigators intend to explore whether EEfRT scores could account for differences in immunological and NF success outcome measures, as defined above (see primary outcome measures).
6 weeks
Secondary Motivational tendencies based on K-means cluster analysis of questionnaires scores Subjects' classification as having approach/avoidance tendencies based on K-means cluster analysis of scores in three questionnaires: SPSRQ, TPQ and NEO-ffi.
The investigators predict that:
i. subjects with approach tendencies will exhibit stronger mesolimbic reward network activations during the MID task and NF task, compared to avoiders.
ii. Approachers will exhibit higher immunological changes as reflected by the main immunological outcome measures, compared to avoiders.
6 week
Secondary Functional connectivity of mesolimbic network during rest fMRI scan Rest scans will be applied at the beginning of the first and at the end of the fourth (last) NF practice session, in order to assess functional changes in the mesolimbic reward circuit following NF training.
The investigators intend to explore whether changes in functional connectivity of the mesolimbic reward network will occur specifically in the mesolimbic fMRI-NF group (compared with control fMRI NF group).
1-3 weeks
Secondary long term immunological effects A sub-group of 30 subjects will arrive for an aditional blood sample session three months following vaccination, in order to assess long term differences in anti-HBs levels.
Exploratory analysis: differences between groups and brain-immune correlations will be examined.
3 months
Secondary Subjective reports of SHAPS (Snaith-Hamilton Pleasure Scale) A 14 items (answered on a four points scale ranging from 'strongly disagree' to 'strongly agree') questionnaire for estimation of the degree of which a person is able to experience pleasure or the anticipation of a pleasurable experience. The questionnaire is scored as the sum of of the items (totals scores ranged from 0 to 14). A higher total score indicates higher levels of anhedonia.
Exploratory Analyses: The investigators will examine whether the questionnaire scores prior to NF practice and vaccination, will account for differences in NF learning and in immunological outcome measures. Moreover, the investigators will track changes in this score along the experiment in order to inspect the relationship between subjective hedonic experience and NF success/immune functioning.
6 weeks
Secondary Subjective reports to Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ) A questionnaire for assessing responsiveness to reward and punishment. The questionnaire includes 48 yes/no questions divided into two scales - sensitivity to punishment (SP) and sensitivity to reward (SR). Each sub-scale score is derived by summation of the reports.
Exploratory analysis: the investigators will examine whether the questionnaire score during the first session (prior to NF practice and vaccination), will account for differences in NF learning and in immunological outcome measures.
6 weeks
Secondary Subjective reports to Tridimensional Personality Questionnaire (TPQ) A questionnaire with 100 true/false items to characterize individual's three traits of personality - reward dependence, harm avoidance and novelty seeking. Each trait has 4 sub-scales that sums to the trait's score.
Exploratory analysis: the investigators will examine whether the questionnaire score during the first session (prior to NF practice and vaccination), will account for differences in NF learning and in immunological outcome measures.
6 weeks
Secondary Autonomic Nervous System (ANS) measure: Heart Rate Variability (HRV) Measurements of HRV are taken during fMRI scans in all NF practices, in order to monitor the activity of the sympathetic system. For each fMRI scan, HRV measures such as average variability and frequency ratios will be calculated.
Exploratory analyses: the investigators suspect the sympathetic system will mediate the correlation between the mesolimbic reward activations and immunological outcome meaures (see primary outcome measures 1 and 2). Therefore, the investigators will explore the link between sympathetic measures taken at TP4 (prior to vaccination) and the correlation between reward mesolimbic activations during TP4 NF practice and the immunological outcome measures described above.
3 days - 4 weeks